Clinical characteristics and outcomes among hospitalized adults with severe COVID-19 admitted to a tertiary medical center and receiving antiviral, antimalarials, glucocorticoids, or immunomodulation with tocilizumab or cyclosporine: A retrospective observational study (COQUIMA cohort)

Autor: Ana Roda-Santacruz, Eva María Martí-Ballesteros, Esther Merino-Lanza, María José Monforte-Gómez, Manuel Recio-Rodríguez, Gabriel Sotres-Fernández, María Correyero-Plaza, Margarita Rodríguez-López, José María Echave-Sustaeta María-Tomé, Elena Almagro-Casado, María Dolores Sánchez-Manzano, Lorena Comeche-Casanova, Margarita Remirez-de-Esparza-Otero, Félix J. La Coma-Lanuza, José Manuel Luque-Pinilla, Pablo Guisado-Vasco, Lucia González-Cortijo, Esteban Javier Malo-Benages, Rocío Diez-Munar, Sofia Valderas-Ortega, Daniel Carnevali-Ruiz, Cristina Andreu-Vázquez, Ruth Barrena-Puertas, Israel Thuissard-Vasallo, Maria Maravillas Carralón-González

Publikováno v: EClinicalMedicine
EClinicalMedicine, Vol 28, Iss, Pp 100591-(2020)
ABACUS. Repositorio de Producción Científica
Universidad Europea (UEM)

Background The COVID-19 outbreak challenges the Spanish health system since March 2020. Some available therapies (antimalarials, antivirals, biological agents) were grounded on clinical case observations or basic science data. The aim of this study i

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::96c7f7ff7dc6b35bda43d71c5aca86bc